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The metabolic syndrome, a cluster of metabolic abnormalities, has been linked to both cardiovascular disease
and type 2 diabetes mellitus risk. Several studies have shown that ethnicity is an important determinant for
risk of developing the metabolic syndrome; therefore, further understanding of the prevalence and
presentation of the metabolic syndrome in various ethnic groups is needed. Latin American communities,
and particularly Andean countries, are largely understudied in relation to the metabolic syndrome and
until recently, the prevalence of this metabolic disturbance in Andean Hispanics was unknown.
Nonetheless, recent (and ongoing) population studies are providing important data regarding the
prevalence and patterns of the metabolic syndrome in various Andean countries. This review aims to
summarize and interpret the information provided by these studies in an effort to better characterize the
metabolic syndrome in Andean Hispanics.The authors report no re-
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CC BY-NC-ND license.Cardiovascular disease is an emergent cause of death in
many Latin American and Andean countries, and it is ex-
pected that its burden will increase in the near future un-
less appropriate control prevention strategies are
implemented [1e6]. To design adequate prevention stra-
tegies, it is necessary to estimate the prevalence, charac-
teristics, and distribution of various cardiovascular risk
factors in these populations. Similarly, validated opera-
tional deﬁnitions will be needed to characterize conditions
associated with increased cardiovascular risk, such as
abdominal obesity and the metabolic syndrome (MetS).
The MetS is a cluster of metabolic abnormalities associated
with elevated risk of cardiovascular morbidity and mor-
tality [7e11]. A recently published joint interim statement
issued by several organizations has established an updated
MetS deﬁnition, recognizing central adiposity, abnormal
glucose regulation, elevated triglycerides, lowered high-
density lipoprotein cholesterol (HDL-C), and elevated
blood pressure as its central components [12]. Prospective
data suggest that death from coronary heart disease is 3
higher among middle-age men with MetS after adjustment
for conventional cardiovascular risk factors [13]. MetS is
also an independent predictor for the development of type
2 diabetes mellitus [11,14]. In a large prospective study,
the risk for diabetes after 7 years of follow-up was more
than 3-fold higher in subjects with MetS, even after the
adjustment for other risk factors for diabetes including
impaired glucose tolerance and impaired fasting insulin
[14].
Several studies have shown that ethnicity and sex are
important determinants for the risk of having MetS
[15e23]. In the United States, NHANES III (Third Na-
tional Health and Nutrition Examination Survey) differ-
ences in the prevalence of MetS between ethnic groups
were clearly observed. African American women andGLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 349-354Mexican American women had higher prevalence rates of
MetS than African American men and Mexican American
men did, respectively, whereas the risk in Caucasians was
similar between sexes [15]. Although several lines of evi-
dence indicated that ethnicity is an important determinant
of the MetS phenotype, until recently, the prevalence of
MetS in Andean communities was largely unknown. An-
dean countries share indigenous population groups and
historic patterns of colonization that have resulted in
comparable genetic admixtures and cultural traditions that
make them very similar. Recently published (and ongoing)
population studies are providing important data regarding
the prevalence and patterns of MetS in different Andean
countries (Table 1). Among the largest of these are the
study of coronary risk factors in the state of Zulia in
Venezuela [15], the PREVENCION (Peruvian Study of
Cardiovascular Disease Prevalence) study in the city of
Arequipa in Peru [23e28], the National Survey of Health
in Chile [29], and the CINDI/CARMEN (Countrywide
Integrated Noncommunicable Disease Intervention Pro-
gramme) study in the Colombian city of Bucaramanga
[30]. Although the latter study did not speciﬁcally assess
the prevalence of MetS [30], it provided important data
regarding the prevalence of obesity and other cardiovas-
cular risk factors in these populations. This paper aims to
summarize and interpret the information provided by these
studies to better characterize the MetS in Andean countries.PREVALENCE OF THE MetS AND ITS COMPONENTS
IN ANDEAN POPULATIONS
One of the ﬁrst large studies assessing the prevalence of the
MetS and its individual components in an Andean popu-
lation was the Zulia study of coronary risk factors [15]. It
included >3,000 subjects from a representative sample349
TABLE 1. Epidemiological studies examining the MetS among Andean Hispanics
Ref. # Study Geographic area
Years of
observation
Sample,
n (% females)
Age range,
yrs Diagnosis criteria
15 Zulia Coronary Heart Disease Risk
Factor Study
Zulia, Venezuela 1999e2001 3,108 (69.6) 20 NCEP ATP III
24 PREVENCION study Arequipa, Peru 2003e2007 1,878 (53.8) 20e80 NCEP ATP III;
AHA/NHLBI
29 National Health Survey in Chile Chile 2003 1,818 (54.2) 17 NCEP ATP III; IDF
30 CINDI/CARMEN study Bucaramanga,
Colombia
2001 2,989 (NA) 15e64 NA
AHA/NHLBI, American Heart Association/National Heart, Lung, and Blood Institute; CINDI/CARMEN, Countrywide Integrated Noncommunicable
Disease Intervention Programme; IDF, International Diabetes Federation; MetS, metabolic syndrome; NA, not available; NCEP ATP III, Third Report of
the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment Panel; PREVENCION, Prevalence and Patterns of
Hypertension in Peruvian Andean Hispanics.
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350from each health district in the Venezuelan state of Zulia.
This study showed that more than 60% of adults had low
levels of HDL-C (deﬁned as a serum level <50 mg/dl in
women and <40 mg/dl in men), and that there were high
age-adjusted prevalences of abdominal obesity (42.9%),
hypertriglyceridemia (32.3%), and high blood pressure
(38.1%) in this population. In contrast, the investigators
reported a relatively low prevalence of abnormal fasting
glucose (10.9%) [15]. Overall, the age-adjusted prevalence
of MetS was 35% among men and 29.8% in women.
Measurement procedures across studies are described in
Appendix 1 (available online).
Another important study that provided national esti-
mates of the prevalence of MetS among Andean Hispanics
was the National Survey in Chile [29]. A total of 1,833
randomly selected adults aged 17 years were included in
the study. Overall, the age-adjusted prevalence of the MetS,
according to the NCEP ATP III (Third Report of the Na-
tional Cholesterol Education Program Expert Panel on
Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults) deﬁnition, was 31.6%, with similar
prevalence estimates across sex (32.7% and 30.8% for men
and women, respectively). In concordance to ﬁndings from
Zulia, this study showed that low HDL-C (deﬁned as a
serum level <50 mg/dl in women and <40 mg/dl in men)
was the most prevalent component of the MetS among
Chilean adults with a prevalence of 52.3%, followed by
hypertension, hypertriglyceridemia, and abdominal obesity
with prevalence rates of 46.0%, 30.3%, and 29.7%,
respectively (95% conﬁdence intervals are shown in
Table 2). In this population, however, the investigators re-
ported a low prevalence of abnormal fasting glucose (22%).
The PREVENCION study subsequently reported data
from a population-based sample of 1,878 adults in Are-
quipa, Peru [24e26]. Comparable to the ﬁndings from
Venezuela and Chile, this study reported very high age-
standardized prevalences of low HDL-cholesterol (32.3%
of men and 60% of women) and signiﬁcant prevalences of
abdominal obesity (15.2% of men and 39.7% of women) as
deﬁned by the NCEP ATP III. The age-standardized
prevalences of hypertriglyceridemia, high blood pressure,and high fasting glucose were 54.2%, 28.2%, and 6.3% in
men, and 38.2%, 25.2%, and 5.9% in women, respectively
[26]. In this population, the prevalence of MetS was 23.2%
in women and 14.3% in men [24]. These data clearly
showed that in Arequipa abdominal obesity and low HDL-
C were signiﬁcantly more frequent among women, whereas
hypertriglyceridemia was more frequent in men. Similar
sex differences in the prevalences of low HDL-C and
hypertriglyceridemia were also reported in the Zulia study.
It is worth noting that sex-speciﬁc HDL-C cutoffs are used
to determine the presence of this MetS component (<50
mg/dl in women and <40 mg/dl in men). Therefore,
although mean levels of HDL-C were comparable between
sexes in Andean Hispanics (i.e., 48.4 and 46.0 mg/dl in
Peruvian men and women, respectively), prevalence of low
HDL-C was strikingly higher in Andean women when
compared with women of other ethnicities. For example,
prevalence estimates of low HDL-C were 68% and 60% for
women in the Zulia [15] and PREVENCION study [24],
respectively; whereas the latest estimates in the United
States indicate only 32% of women present this component
[31]. Similar comparisons have been presented in a
recently published paper by the Latin American Con-
sortium of Studies in Obesity [32].
As shown in Table 2, another similarity between the
Zulia and the PREVENCION study populations was the
higher prevalence of abdominal obesity among women
versus men. In contrast, a signiﬁcantly greater prevalence
of elevated blood pressure was noted in Zulia’s men and
accounted for the high overall prevalence of the MetS
among men in this population. In Arequipa, the prevalence
of high blood pressure was similar across sexes (see
Table 2). It appears that the risk of MetS and abdominal
obesity in Andean populations increases steeply with age,
particularly in women. Before age 50 years, no signiﬁcant
sex differences in the prevalence of the MetS were found in
the PREVENCION study (13.5% vs. 10% in women and
men, respectively; p ¼ NS); whereas at or after age 50
years, the prevalence was nearly twice as high among
women than men (52.8% vs. 27.8%; p < 0.0001). The
prevalence of abdominal obesity in Arequipa wasGLOBAL HEART, VOL. 8, NO. 4, 2013
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TABLE 2. Age-adjusted prevalence rates of the metabolic syndrome and its components by sex
Venezuela [15] Peru [24] Chile [29] Colombia [30]
Abdominal obesity*
Overall 42.9 (41.2e44.6) NA 29.7 (26.6e33.0) 13.2 (12.0e14.6)
Men 31.4 (28.4e34.4) 15.2 (12.8e18.11) NA 6.1 (4.7e7.8)
Women 47.9 (45.8e50.0) 39.7 (36.3e43.2) NA 17.0 (15.3e18.8)
Low HDL-Cy
Overall 65.3 (63.6e67.0) NA 52.6 (48.7e55.6) 27.7 (25.9e29.6)
Men 59.9 (56.8e63.0) 32.3 (28.7e36.1) NA 37.6 (34.5e40.9)
Women 67.5 (65.5e69.4) 60.0 (56.2e63.6) NA 22.2 (20.2e24.4)
Hypertriglyceridemiaz
Overall 32.3 (30.7e34.0) NA 30.0 (27.0e33.2) NA
Men 43.1 (39.9e46.3) 54.2 (50.3e58.1) NA NA
Women 27.8 (25.9e29.7) 38.2 (35.0e41.5) NA NA
Hypertensionx
Overall 37.1 (36.4e39.9) NA 46.0 (42.5e49.6) 9.5 (9.4e9.6)
Men 53.3 (50.1e56.5) 28.2 (25.2e31.6) NA 8.8 (8.6e9.0)
Women 31.5 (29.6e33.5) 25.2 (22.6e28.0) NA 9.9 (9.8e10.0)
Elevated fasting blood glucosek
Overall 10.9 (9.8e12.0) NA 22.0 (19.0e25.4) 5.8 (4.7e7.2)
Men 13.1 (11.1e15.4) 6.3 (4.9e8.0) NA 7.0 (5.2e9.5)
Women 10.0 (8.8e11.3) 5.9 (4.6e7.4) NA 5.1 (4.0e6.6)
Metabolic syndrome{
Overall 31.2 (29.6e32.9) 18.1 (16.1e20.2) 31.6 (28.6e35.1) NA
Men 35.0 (32.0e38.1) 14.3 (11.9e17.1) 32.7 (28.3e37.5) NA
Women 29.8 (27.9e31.8) 23.2 (20.4e26.2) 30.8 (26.7e35.2) NA
Values are percentages (95% conﬁdence intervals). HDL-C, high-density lipoprotein cholesterol; NA, not available.
*Waist circumference over 102 cm in men and over 88 cm in women.
yHDL-C <40 mg/dl in men and <50 mg/dl in women.
zSerum triglycerides 150 mg/dl.
xBlood pressure of 130/85 mm Hg.
kFasting blood glucose of 110 mg/dl (Zulia) or 100 mg/dl (Arequipa).
{Three or more of the abovementioned abnormalities.
gREVIEWjparticularly high among women 50 years of age (61.9%)
[24]. Similar ﬁndings have been reported in other Andean
populations, where sex differences in the prevalence of
abdominal obesity occurred predominantly in older
groups, particularly among older women. For example, the
CINDI/CARMEN study, a study on cardiovascular risk
factors among Colombian adults aged 15 to 64 years
showed the prevalence of abdominal obesity among
women between the ages of 60 and 64 was 41.7%, in sharp
contrast with the low prevalence rates of abdominal obesity
reported in all male groups, including men older than 60
years. The prevalence of abdominal obesity deﬁned by the
NCEP ATP III criteria was 13.6% in men between the ages
of 60 and 64 years [30]. Prevalence estimates of other MetS
components in the CINDI/CARMEN study in Bucar-
amanga, Colombia, including hypertension, low HDL-C,
and abnormal fasting glucose, are presented in Table 2.
Available data suggest that older Andean women not
only have a higher prevalence of abdominal obesity, but
they also tend to have more components of the MetS. In
the PREVENCION study, independent analyses by sexGLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 349-354showed that the odds ratio for the risk of MetS associated
with a 10-year increase in age was 2.03 among women
versus 1.61 among men (p < 0.003) (Table 3). When
analyzing the odds ratio associated with a 10-year
increase in age for the individual MetS components, the
greatest difference between men and women was found
in the prevalence of hypertension, followed by hyper-
triglyceridemia and abdominal obesity (Table 3).
Another interesting ﬁnding from the PREVENCION
study was that the risk of having low HDL-C did not in-
crease with age, in contrast with the other components of
the MetS (Table 3) [24]. The reason for this epidemiologic
dissociation is unclear but could be explained by several
factors. First, it is possible that a survival bias is present, so
that subjects with low HDL-C have a premature mortality,
leading to a lower prevalence of this dyslipidemia pattern
in older-age subjects. However, high cardiovascular mor-
tality in younger-age groups has been found to occur
in later stages of the epidemiologic transition, when the
shift from infectious and deﬁciency diseases to the pre-
ponderance of noncommunicable, chronic illnesses occurs.351
TABLE 3. Odds ratio associated with a 10-year increase in age for the risk of MetS and its components according to AHA/NHLBI criteria
in men and women
Men* Women*
OR (95% CI) p value OR (95% CI) p value
p value for age by
sex interactiony
Metabolic syndrome 1.61 (1.44e1.79) <0.0001 2.03 (1.82e2.28) <0.0001 0.003
Abdominal obesity 1.45 (1.31e1.60) <0.0001 1.62 (1.48e1.79) <0.0001 0.09
High triglycerides 1.38 (1.26e1.52) <0.0001 1.66 (1.51e1.83) <0.0001 0.008
Elevated fasting glucose 1.90 (1.62e2.22) <0.0001 2.12 (1.81e2.47) <0.0001 0.33
Low HDL-C 0.99 (0.91e1.09) NS 0.90 (0.83e0.98) 0.02 0.13
High blood pressure 1.96 (1.74e2.20) <0.0001 2.80 (2.43e3.23) <0.0001 <0.0001
CI, conﬁdence interval; NS, not signiﬁcant; OR, odds ratio; other abbreviations as in Tables 1 and 2.
*Odds ratios associated with increased risk of MetS and its components among men and women for every 10-year increase in age.
yThe p value for age-sex interaction as a predictor of risk of MetS and its components.
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ologic transition, making it unlikely that an important
survival bias occurred in younger-adult age groups.
Another possible explanation could be the presence of
genetic polymorphisms associated with lower HDL-C
levels, which could explain the high prevalence of low
HDL-C in these populations, including the younger
groups. Dietary and other cultural patterns may also play a
role. To clarify these ﬁndings, carefully designed genetic
epidemiologic studies, as well as prospective studies
looking at changes on the levels of HDL-C with aging and
the effects of different dyslipidemia patterns on cardio-
vascular and total mortality are required.
Based on the abovementioned data, it appears that the
phenotypic pattern of the MetS in Andean adults is charac-
terized by: 1) a high prevalence of abdominal obesity when
the NCEP ATP III and American Heart Association/National
Heart, Lung, and Blood Institute (AHA/NHLBI) abdominal
obesity criteria are used, particularly in older women; 2)
a high prevalence of dyslipidemia, with low HDL-C
levels being particularly prevalent in women and hyper-
triglyceridemia being particularly prevalent inmen; and 3) an
increase in theprevalenceofMetSwith aging that is sharper in
women than in men and that is explained by a greater age-
related increase in the prevalence of abdominal obesity,
hypertriglyceridemia, and high blood pressure in women.OPTIMAL DEFINITIONS OF ABDOMINAL OBESITY
AND MetS IN ANDEAN POPULATIONS
The seemingly high rates of abdominal obesity among
Andean adults raise the question of what is actually the
correct deﬁnition of abdominal obesity for these pop-
ulations. The most commonly used deﬁnitions in the
studies described in this review are those from the AHA/
NHLBI [33] and the NCEP ATP III [34]. A deﬁnition from
the International Diabetes Federation (IDF) had also been
proposed [35]. According to the NCEP ATP III, the MetS
is deﬁned by the presence of 3 of the followingcomponents: 1) abdominal obesity, deﬁned as a waist
circumference >102 cm in men and >88 cm in women; 2)
elevated triglycerides (>150 mg/dl); 3) low HDL-
cholesterol (<40 mg/dl in men or <50 mg/dl in women);
4) high fasting glucose (110 mg/dl); 5) high blood pres-
sure (systolic blood pressure 130 mm Hg or diastolic
blood pressure 85 mm Hg, or use of pharmacologic
treatment for hypertension). The subsequent AHA/NHLBI
criteria decreased the cutoff to deﬁne abnormal fasting
glucose to >100 mg/dl (instead of 110 mg/dl) and identi-
ﬁed the use of ﬁbrates or niacin as markers of high tri-
glyceride levels or low HDL-cholesterol. The main
difference between the IDF criteria and the criteria pro-
posed by the NCEP ATP III and AHA/NHLBI lies in the
deﬁnition of abdominal obesity. The IDF criteria included
different cutoff values to identify abdominal obesity ac-
cording to ethnicity and required the presence of abdominal
obesity for the diagnosis of MetS. In an effort to harmonize
the deﬁnition of MetS, a joint interim statement of various
international organizations, including the IDF, NHLBI,
AHA, World Heart Federation, International Atheroscle-
rosis Society, and the International Association for the
Study of Obesity, was published in 2009 [12]. The updated
deﬁnition resembled that of the AHA/NHLBI, however, it
included population- and country-speciﬁc deﬁnitions of
abdominal obesity. It recommended that the IDF cut points
be used for non-European populations, such as Andean
Hispanics. Due to the lack of studies in South American and
Central American populations, the IDF recommended the
use of the cutoff values proposed for South Asian pop-
ulations, which deﬁned abdominal obesity as waist
circumference of 90 cm in men and 80 cm in women,
until more speciﬁc data are available [35].
Clearly, the use of different operating deﬁnitions can
lead to important differences in the prevalence estimates
of MetS in Andean and other Latin American or Hispanic
populations. A study that compared the prevalences of
MetS in San Antonio, Texas, USA; Mexico City; Spain;
and Peru found that the IDF deﬁnition generated higherGLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 349-354
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prevalence estimates than the NCEP ATP III deﬁnition
did [22]. Prevalence differences were more signiﬁcant in
men of Mexican and Peruvian Mestizo ethnic origin than
in Europid subjects. The kappa coefﬁcient of agreement
between the ATP III and IDF deﬁnitions was only 0.54 in
Peruvian men. Even more importantly, it should be noted
that the available MetS and abdominal obesity prevalences
from these studies were estimated using cut points rec-
ommended for Caucasian (ATP III and AHA/NHLBI) and
South Asian populations (IDF). Whether these cut points
were adequate for Andean adults was unknown at the
time of these reports. At least 2 previous studies in men
from Colombia and Ecuador suggested that the cutoffs to
deﬁne abdominal obesity in Andean adults should be
different from those for Caucasians [36,37]. A recently
published study from the PREVENCION investigators
[25] aimed to assess the optimal deﬁnitions for abdominal
obesity in Andean adults by establishing the relationship
of different waist circumference cut points with the
presence of clinically apparent cardiovascular disease as
well as with the presence of subclinical atherosclerosis
assessed by carotid intima-media thickness, a validated
independent surrogate marker for the risk of future
cardiovascular events in the general population [38,39].
After identifying the normal values of intimal thickness in
a highly selected healthy reference sample free of car-
diovascular risk factors, receiver-operating characteristic
curves were constructed on the basis of the detection of
abnormally high carotid intimal thickness with different
cut points of waist circumference in men and women.
Similar analyses were performed using the presence of
clinically established cardiovascular disease as an
endpoint. Results consistently indicated that optimal cut
points associated with subclinical atherosclerosis and
clinically evident cardiovascular diseases were lower than
the ones recommended for Caucasians by the NCEP ATP
III in both men and women. The optimal cut points for
waist circumference were found to be >97 cm in men
and >87 cm in women [25]. Using these optimal cutoffs,
a modiﬁed updated ethnic-speciﬁc MetS deﬁnition
generated slightly higher prevalence estimates than the
AHA/NHLBI deﬁnition did, particularly among men. The
original AHA/NHLBI and updated deﬁnitions differed in
classifying 4.4% of men (kappa ¼ 0.85) and 1.3% of
women (kappa ¼ 0.99). Also, using these optimal cut
points, individuals who met the ethnic-speciﬁc updated
MetS criteria (and not the original AHA/NHLBI criteria)
demonstrated higher carotid intima-media thickness than
subjects who did not have MetS by either criteria, indi-
cating that the more sensitive updated classiﬁcation is not
spurious but rather associated with early vascular disease.
These ﬁndings are important because they provide pre-
liminary deﬁnitions of abdominal obesity for the purpose
of atherosclerotic risk assessment and identify a useful
ethnic-speciﬁc MetS deﬁnition in Andean adults until
more deﬁnitive prospective data become available.GLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 349-354CLINICAL IMPLICATIONS AND FUTURE
PERSPECTIVES
Given the association of the MetS with an increased risk of
cardiovascular disease and type 2 diabetes mellitus, the
high prevalence of MetS in Andean populations has high
clinical and epidemiologic relevance. Data have emerged
from Andean populations describing distinct patterns of
the MetS (with high prevalence of abdominal obesity and
dyslipidemia, including low HDL levels and hyper-
triglyceridemia). An operative deﬁnition for abdominal
obesity in this population is now available and should be
implemented in detection programs. This deﬁnition also
provides clinicians with adequate cut points for waist
circumference to use in the diagnosis of MetS among An-
dean Hispanics.
Available prevalence data of these and other cardio-
vascular risk factors could be used to target prevention
strategies and to estimate the cost-beneﬁt ratio for various
potential interventions in the region. However, there are still
important challenges for the future, including the design of
longitudinal studies aimed to establish the absolute risk of
cardiovascular events and to validate surrogate markers of
cardiovascular outcomes in Andean populations.REFERENCES
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APPENDIXAPPENDIX 1. Measurement procedures across studies
Zulia Coronary Heart
Disease Risk Factor
Study PREVENCION study
National Health Survey
in Chile CINDI/CARMEN study
Waist circumference Measured at umbilical
level while subjects
were standing with
weight equally
distributed on both
feet
Measured at umbilical
level while
subjects were
standing with
weight equally
distributed on
both feet
Measured at umbilical
level while subjects
were standing with
weight equally
distributed on both
feet
Measured at umbilical
level while
subjects were
standing with
weight equally
distributed on
both feet
Blood pressure Measured twice after
participant was
seated for 5 min
Measured between 7
and 10 AM
according to
recommendations
from the Seventh
Report of the Joint
National
Committee for the
Diagnosis,
Evaluation, and
Treatment of High
Blood Pressure
Measured twice after
participant was
seated for 5 min
during the morning
hours
Blood pressure was
measured
independently by 2
observers in each
participant,
following standard
recommendations
Lipids Sample of venous blood
was drawn after
12e14 h of
overnight fasting
and was centrifuged
within 30e45 min
of collection
Samples of venous
blood were
obtained after 8
h of fasting and
serum was used
for biochemical
measurements
Samples of venous
blood were
obtained after 9 h
of fasting and serum
was used for
biochemical
measurements
Fasting blood samples
were drawn from
each participant
and processed and
stored at e70C
CINDI/CARMEN, Countrywide Integrated Noncommunicable Disease Intervention Programme; PREVENCION, Prevalence and Patterns of Hyper-
tension in Peruvian Andean Hispanics.
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